← Leaderboards
Asfar S Azmi
Wayne State University
$3,644,683
Attributed
$4,702,122
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $737.7K · FY2015–25$1M$750K$500K$250K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,702,122 · 4
By mechanism
R37$2,429,928 · 1
R01$1,748,753 · 1
R21$366,125 · 1
P30$157,316 · 1
Top collaborators
- Bassel El-Rayes5 shared
- Ramzi M. Mohammad2 shared
Most similar at Wayne State University
Same institution · by research overlap
- Robert R Freedman$15,174,313
- Eric Andrew Woodcock$1,217,448
- David M Ledgerwood$4,177,501
- Stephen E Dicarlo$5,724,182
- Mark K. Greenwald$16,108,394
Others in their field
Top investigators on “Novel Therapeutics”
- David Heimbrook · Leidos Biomedical Research, Inc.$355,066,875
- Judith S. Currier · University Of California Los Angeles$321,442,024
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Leonard Freedman · Leidos Biomedical Research, Inc.$263,124,404
- Daniel R Kuritzkes · Brigham And Women'S Hospital$246,024,897
- Sharon A Nachman · Johns Hopkins University$212,395,175
Research focus
Novel TherapeuticsPathway InteractionsPharmaceutical PreparationsTumorTreatment ResponsePharmacodynamic BiomarkerPreclinical StudyProteinsSignal TransductionResistanceRna InterferenceOverexpressionPre-ClinicalNuclearIn VivoRegimenResponse BiomarkerClinical TrialsAnalogCrispr/Cas TechnologyGenesOrganoidsSubcutaneousMolecular
Grant awards (17)
Molecular Therapeutics$45,034
P30 · FY2025 · CA · contact PI
A novel therapy for pancreatic neuroendocrine tumors$336,000
R01 · FY2024 · CA · contact PI
Clinical Translation of Nuclear Export Inhibitor in Metastatic Pancreatic Cancer$334,251
R37 · FY2024 · CA · contact PI
Molecular Therapeutics$66,034
P30 · FY2024 · CA · contact PI
A novel therapy for pancreatic neuroendocrine tumors$346,592
R01 · FY2023 · CA · contact PI
Clinical Translation of Nuclear Export Inhibitor in Metastatic Pancreatic Cancer$344,871
R37 · FY2023 · CA · contact PI
Molecular Therapeutics$46,248
P30 · FY2023 · CA · contact PI
Clinical Translation of Nuclear Export Inhibitor in Metastatic Pancreatic Cancer$352,275
R37 · FY2022 · CA · contact PI
A novel therapy for pancreatic neuroendocrine tumors$346,572
R01 · FY2022 · CA · contact PI
A novel therapy for pancreatic neuroendocrine tumors$353,627
R01 · FY2021 · CA · contact PI
Clinical Translation of Nuclear Export Inhibitor in Metastatic Pancreatic Cancer$352,275
R37 · FY2021 · CA · contact PI
A novel therapy for pancreatic neuroendocrine tumors$365,962
R01 · FY2020 · CA · contact PI
Clinical Translation of Nuclear Export Inhibitor in Metastatic Pancreatic Cancer$352,275
R37 · FY2020 · CA · contact PI
Clinical Translation of Nuclear Export Inhibitor in Metastatic Pancreatic Cancer$341,706
R37 · FY2019 · CA · contact PI
Clinical Translation of Nuclear Export Inhibitor in Metastatic Pancreatic Cancer$352,275
R37 · FY2018 · CA · contact PI
Targeting PAK4 for Overcoming Drug Resistance in Pancreatic Cancer$166,840
R21 · FY2016 · CA · contact PI
Targeting PAK4 for Overcoming Drug Resistance in Pancreatic Cancer$199,285
R21 · FY2015 · CA · contact PI